LinkedIn Profile

Access Ruiyibio historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:ruiyibio-2 3615267 Dec 3rd, 2020 12:00AM RuiYi, Inc. 181 18.00 Open Research Dec 3rd, 2020 12:46PM Dec 3rd, 2020 12:46PM RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS"​) was developed internally under the direction of scientific founder Ray Stevens. Open 505 Coast Blvd South Ste 300 La Jolla CA US 92037 Pharmaceuticals & Biotechnology
private:ruiyibio-2 3615267 Dec 2nd, 2020 12:00AM RuiYi, Inc. 181 18.00 Open Research Dec 2nd, 2020 04:05PM Dec 2nd, 2020 04:05PM RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS"​) was developed internally under the direction of scientific founder Ray Stevens. Open 505 Coast Blvd South Ste 300 La Jolla CA US 92037 Pharmaceuticals & Biotechnology
private:ruiyibio-2 3615267 Dec 1st, 2020 12:00AM RuiYi, Inc. 181 18.00 Open Research Dec 1st, 2020 02:32PM Dec 1st, 2020 02:32PM RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS"​) was developed internally under the direction of scientific founder Ray Stevens. Open 505 Coast Blvd South Ste 300 La Jolla CA US 92037 Pharmaceuticals & Biotechnology
private:ruiyibio-2 3615267 Nov 30th, 2020 12:00AM RuiYi, Inc. 181 18.00 Open Research Nov 29th, 2020 08:35PM Nov 30th, 2020 03:23PM RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS"​) was developed internally under the direction of scientific founder Ray Stevens. Open 505 Coast Blvd South Ste 300 La Jolla CA US 92037 Pharmaceuticals & Biotechnology
private:ruiyibio-2 3615267 Nov 28th, 2020 12:00AM RuiYi, Inc. 181 18.00 Open Research Nov 28th, 2020 04:10PM Nov 28th, 2020 04:10PM RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS"​) was developed internally under the direction of scientific founder Ray Stevens. Open 505 Coast Blvd South Ste 300 La Jolla CA US 92037 Pharmaceuticals & Biotechnology
private:ruiyibio-2 3615267 Nov 27th, 2020 12:00AM RuiYi, Inc. 181 18.00 Open Research Nov 27th, 2020 12:35PM Nov 27th, 2020 12:35PM RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS"​) was developed internally under the direction of scientific founder Ray Stevens. Open 505 Coast Blvd South Ste 300 La Jolla CA US 92037 Pharmaceuticals & Biotechnology
private:ruiyibio-2 3615267 Nov 26th, 2020 12:00AM RuiYi, Inc. 181 18.00 Open Research Nov 25th, 2020 07:21PM Nov 26th, 2020 01:34PM RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS"​) was developed internally under the direction of scientific founder Ray Stevens. Open 505 Coast Blvd South Ste 300 La Jolla CA US 92037 Pharmaceuticals & Biotechnology
private:ruiyibio-2 3615267 Nov 24th, 2020 12:00AM RuiYi, Inc. 182 18.00 Open Research Nov 24th, 2020 02:43PM Nov 24th, 2020 02:43PM RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS"​) was developed internally under the direction of scientific founder Ray Stevens. Open 505 Coast Blvd South Ste 300 La Jolla CA US 92037 Pharmaceuticals & Biotechnology
private:ruiyibio-2 3615267 Nov 23rd, 2020 12:00AM RuiYi, Inc. 182 18.00 Open Research Nov 23rd, 2020 04:41PM Nov 23rd, 2020 04:41PM RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS"​) was developed internally under the direction of scientific founder Ray Stevens. Open 505 Coast Blvd South Ste 300 La Jolla CA US 92037 Pharmaceuticals & Biotechnology
private:ruiyibio-2 3615267 Nov 22nd, 2020 12:00AM RuiYi, Inc. 182 9.00 Open Research Nov 22nd, 2020 03:38PM Nov 22nd, 2020 03:38PM RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS"​) was developed internally under the direction of scientific founder Ray Stevens. Open 505 Coast Blvd South Ste 300 La Jolla CA US 92037 Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.